Thus, suppressing the ability of circulating cancer cells to survive in the bloodstream and initiate metastatic growth through the HECTD4–COX-2 axis reported here highlights a therapeutic opportunity, which may warrant clinical investigation of metastasis prevention in carefully selected clinical contexts. This evidence concerns the gene HECTD4 and cancer.